Pharmaceutical compositions containing a 2-(furyl-methyl)-6,7-benzomorphan and method of use

ABSTRACT

Pharmaceutical dosage unit compositions containing as the active ingredient a compound of the formula   WHEREIN R is hydrogen, methyl or acetyl, R1 is hydrogen, methyl, ethyl, n-propyl, isopropyl or butyl, and R2 and R3 are each hydrogen, methyl or ethyl, OR A NON-TOXIC, PHARMACOLOGICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; AND A METHOD OF USING THE SAME AS OPIATE ANTAGONISTS, NON-NARCOTIC ANALGESICS AND ANTITUSSIVES.

United States Patent [191 Merz et al.

[ June 3, 1975 [75] Inventors: Herbert Merz; Adolf Langbein;

Helniut Wick; Klaus Stockhaus, all of lngelheim am Rhein, Germany [73] Assignee: Boehringer lngelheim Gmbll,

lngelheim am Rhein, Germany 22 Filed: Jan. 24, 1974 21 Appl. No.: 436,168

Related US. Application Data [62] Division of Ser. No. 222,669, Feb. 1, 1972, Pat. No.

[30] Foreign Application Priority Data Feb. 8, 1971 Germany 2105743 Feb. 25, 1971 Germany 2108954 [52] US. Cl. 424/267 [51] Int. Cl A61k 27/00 [58] Field of Search 424/267 [56] References Cited UNlTED STATES PATENTS 2,924,603 2/1960 Gordon et a1 260/293.54 3,138,603 6/1964 May 424/267 3,250,678 5/1966 Archer 424/267 3,351,626 11/1967 Bartels-Keith et al. 260/293.54

Primary ExaminerAlbert T. Meyers Assistant Examiner-Norman A. Drezin Attorney, Agent, or F irmHammond & Littell [57] ABSTRACT Pharmaceutical dosage unit compositions containing as the active ingredient a compound of the formula 1r cs E341 wherein R is hydrogen, methyl or acetyl,

R is hydrogen, methyl, ethyl, n-propyl, isopropyl or butyl, and

R and R are each hydrogen, methyl or ethyl, or a non-toxic, pharmacologically acceptable acid addition salt thereof; and a method of using the same as opiate antagonists, non-narcotic analgesics and antitussives.

13 Claims, No Drawings wherein R is hydrogen, methyl or acetyl,

R is hydrogen, methyl, ethyl, n-propyl, isopropyl or butyl, preferably hydrogen, and

R and R are each hydrogen, methyl or ethyl, or a non-toxic, pharmacologically acceptable acid addition salt thereof.

In formula I the substituents R and R are in cisconfiguration. The compounds are optically active. Thus, formula I embraces optically inactive racemates or racemic mixtures, as well as the pure optical isomers.

The compounds embraced by formula I may be prepared by a number of different methods, among which the following, each starting from a benzomorphan of the formula R is hydrogen, alkyl, aralkyl or acyl, have proved to be particularly convenient and efficient.

Method A The reaction sequence for this method may be schematically represented as follows:

X-CHg-E i-Z R1 l -H where R H, CH CH CO R2 CH3, C2H5, H

R H, alkyl, aralkyl, acyl Z H, CH C l-l or a substituent which can be converted into H, CH or C H and X halogen, preferably chlorine or bromine, alkyl- SO -O or aryl-SO -O.

More particularly, the preparation of a compound of the formula I by this method comprises reacting a 6,7- benzomorphan of the formula II with a furan derivative of the formula III to form a compound of the formula IV; if Z in intermediate IV is other than the ultimately desired meaning of R converting substitutent Z by chemical reaction into hydrogen, methyl or ethyl to form an intermediate of the formula lVa; if R, in intermediate lVa is other than hydrogen and R in the end product of the formula I is to be hydrogen, deacylating or dealkylating the intermediate Na, and, if R in the end product of the formula I is to be methyl or acetyl, optionally methylating or acetylating the intermediate of the formula IVa wherein R is hydrogen.

The benzomorphan of the formula II is reacted with the calculated amount or a slight excess of the furan derivative of the formula III in the presence of an acidbinding agent. Examples of suitable acid-binding agents are amines, such as trimethylamine or dicyclohexylethylamine; alkali metal carbonates, such as sodium carbonate or potassium carbonate; alkali metal bicarbonates, preferably sodium bicarbonate; metal hydroxides; and metal oxides. The reaction is advantageously performed in the presence of an inert organic solvent medium, such as tetrahydrofuran, dioxane, methylene chloride, dimethylformamide, dimethylsulfoxide, or preferably a mixture of tetrahydrofuran and dimethylformamide. The reaction temperature is variable between wide limits, but temperatures between C. and the boiling point of the particular solvent medium are preferred.

The other reactions of this method are performed in accordance with conventional procedures, and the reaction products are isolated and crystallized in conventional fashion.

Method B The reaction sequence for this method may be schematically represented as follows:

\ i none @z i when R {R I' 1 1 21 ll 3 where R H, CH3, 1 3, z s, 3 7a s w 4 9, H 2 3, 2 4, H 3 3, z s R H, alkyl, aralkyl, acyl, and

Z H, CH C H or a substituent which can be converted into H, CH or C H More particularly, the preparation of a compound of the formula I by this method comprises reacting a 6,7- benzomorphan of the formula II with formaldehyde and a furan derivative of the formula V to form a compound of the formula IV; if Z in intermediate IV is other than the ultimately desired meaning of R converting substituent Z by chemical reaction into hydrogen, methyl or ethyl to form an intermediate of the formula IVa; if R., in intermediate lVa is other than hydrogen and R in the end product of the formula I is to be hydrogen, deacylating or dealkylating the intermediate lVa; and, if R in the end product of the formula I is to be methyl or acetyl, optionally methylating or acetylating the intermediate of the formula IVa wherein R is hydrogen.

The reaction of the benzomorphan of the formula II with formaldehyde and the furan derivative of the formula V is effected in an aqueous solution of a weak acid, especially of acetic acid, and preferably in aqueous 50% acetic acid. Other suitable solvent media are water, alcohols, tetrahydrofuran, dioxane or the like, as well as mixtures of two or more of these. The calculated amount or a slight excess of the furan derivative of the formula V is provided in solution or suspension in the solvent medium. The formaldehyde may be provided in the form of paraformaldehyde or preferably in aqueous solution; in either case it is provided in the calculated amount or in excess thereover. The reaction may be performed at a temperature between -l0C.

Method C The reaction sequence for this method may be schematically represented as follows 0 lie/catalyst Or HCOOH lwhen Zf' R linen Rqf R R N-CHg-fin where R H, CH CH CO R2 CH3, C2H5, H

R H, alkyl, aralkyl, acyl, and

Z H, CH C H or a substituent which can be converted into H, CH or C H More particularly, the preparation of a compound of the formula I by this method comprises reacting a6,7- benzomorphan of the formula II with a furaldehyde of the formula VI in the presence of catalytically activated hydrogen or of formic acid to form a compound of the formula IV; if Z in intermediate IV is other than the ultimately desired meaning of R converting substituent Z by chemical reaction into hydrogen, methyl or ethyl to form an intermediate of the formula lVa; if R, in intermediate [Va is other than hydrogen and R in the end product of the formula I is to be hydrogen, deacylating or dealkylating the intermediate Na; and, if R in the end product of the formula I is to be methyl or acetyl, optionally methylating or acetylating the intermediate of the formula lVa wherein R is hydrogen.

For the reductive alkylation in the presence of catalytically activated hydrogen the aldehyde of the formula VI is provided in the calculated amount or in excess, preferably in a ratio of up to 2 mols of aldehyde per mol of benzomorphan. The reaction is performed in a suitable inert solvent, such as an alkanol, preferably in methanol or ethanol. Any desired hydrogenation catalyst may be used, such as Raney nickel and related catalysts, or also noble metal catalysts, such as palladium or platinum contact catalysts; the latter may be used in finely divided form either free or applied to conventional carriers, such as charcoal, barium sulfate, calcium carbonate, infusorial earth or the like. If necessary, the activity of the catalyst may be reduced, such as by sulfidation, to avoid undesired side-reactions. The amount of catalyst is not critical and may therefore vary within wide limits. The hydrogenation is advantageously performed at atmospheric pressure or at slightly elevated pressure, preferably at l to 3 atmospheres gauge, accompanied by stirring or shaking. High reaction temperatures favor side-ractions; therefore, it is preferred to carry out the reductive alkylation at room temperature or moderately elevated temperatures up to about 60C. The reaction product is isolated and crystallized by conventional methods.

The reaction of a benzomorphan of the formula II with an aldehyde of the formula VI in the presence of formic acid is preferably performed in aqueous solution, but will also proceed in an organic solvent medium. The aldehyde of the formula VI is provided in the calculated amount or in slight excess thereover, preferably in an amount of up to 1.5 mols per mol of benzomorphan. The formic acid is advantageously provided in substantial excess, preferably in an amount of up to 10 mols per mol of benzomorphan. The reaction is carried out at a temperature between 50 and 200C, preferably at to C. The reaction product is isolated and crystallized by conventional procedures.

The other reactions of this method are performed in accordance with conventional procedures, and the reaction products are isolated and crystallized in conventional fashion.

Method D The reaction sequence for this method may be schematically represented as follows:

1 H (VII) (VIII) inhen Z R (IVa) i when R R where R H, CH3,

R2 CH3, C2H5, H

R H, alkyl, aralkyl, acyl, and

Z H, CH C I-I or a substituent which can be converted into H, CH or C I-I More particularly, the preparation of a compound of the formula I by this method comprises reacting a 6,7- benzomorphan of the formula II with a furan carboxylic acid chloride of the formula VII to form a compound of the formula VIII and reducing the same to a compound of the formula IV: if Z in intermediate IV is other than the ultimately desired meaning of R converting substituent Z by chemical reaction into hydrogen, methyl or ethyl to form an intermediate of the formula IVa; if R, in intermediate IVa is other than hydrogen and R in the end product of the formula I is to be hydrogen, deacylating or dealkylating the intermediate IVa; and, if R in the end product of the formula I is to be methyl or acetyl, optionally methylating or acetylating the intermediate of the formula IVa wherein R is hydrogen.

The first step of the reaction sequence, i.e. the formation of an N-furoyl-benzomorphan of the formula VIII, is effected by the Schotten-Baumann method [see C. Schotten, Berichte 17, 2544 (1884); and E. Baumann,

Berichte 19, 3218 (1886)]. If the starting compound of the formula II is one wherein R is hydrogen, i.e., a 2'-hydroxy-6,7-benzomorphan, and the furancarboxylic acid chloride of the formula VII is provided in a ratio of 2 mols per mol of benzomorphan, the reaction product of the formula VIII is an N,O-difuroyl-6,7- benzomorphan, i.e., R is identical to the N-substituent.

In the second step of the reaction sequence the intermediate carboxylic acid amide of the formula VIII is reduced to form a 2-furylmethyl-6,7-benzomorphan of the formula IV. Among the various suitable reduction methods it is preferred to use the reduction with a complex metal hydride, especially with lithium aluminum hydride. The complex hydride is provided in the calculated amount or, more advantageously, in excess up to twice the calculated amount. The reduction is performed in a suitable inert solvent medium, such as an ether or a mixture of ethers, and preferably in tetrahydrofuran. The reaction temperature may vary within wide limits, but the preferred range is between 0C. and the boiling point of the particular solvent medium. If the complex metal hydride reduction is applied to an N,O-difuroyl-6,7-benzomorphan of the formula VIII, not only the carbonyl group of the N-substituent is reduced, but also the O-acyl substituent in the 2'-positi0n is split off simultaneously, whereby a compound of the formula IV wherein R is hydrogen, is obtained.

The other reactions of this method are performed in accordance .with conventional procedures, and the reaction products are isolated and crystallized in conventional fashion.

In a compound of the formula IV the substituent Z may have the same meanings as R, or may also be a substituent which may be converted into hydrogen, methyl or ethyl, such as carboxyl, formyl, hydroxymethyl, acetyl, formylmethyl or halogen, preferably chlorine or bromine Thus, if Z in formula IV is a carboxyl group, the intermediate may be converted into a compound of the formula IVa wherein R is hydrogen by decarboxylation. If Z in formula IV is formyl, hydroxymethyl, acetyl or formylmethyl, the intermediate may be converted into a compound of the formula IVa wherein R is methyl or ethyl by reducion pursuant to known methods, such as catalytic hydrogenation, with sodium/alcohol, with nascent hydrogen generated by zinc/acetic acid, or by the Wolff-Kishner Reduction. Finally, if Z in formula IV is halogen, preferably chlorine or bromine, the intermediate may be converted into a compound of the formula IVa wherein R is hydrogen by catalytic reduction.

The starting compounds required for methods A through D, i.e., the nor-benzomorphans of the formula II, are known compounds and may be prepared by conventional methods. The starting compounds may be optically inactive racemates or optically active antipodes; if the starting compound in methods A through D is a racemate or racemic mixture, the end product of the formula I is also a racemeate or racemic mixture, which may subsequently be separated into its optically active antipode components by conventional methods. Analogously, if the starting compound is an optically active nor-benzomorphan, the end product is the corresponding optically active compound of the formula I.

Using the above-described methods, the following specific compounds of the formula I may be prepared:

13 2-Furfuryl-2'-methoxy-5-methyl-6,7-benzomorphan 2-Furfuryl-2'-methoxy-5-ethyl-6,'7-benzomorphan 2-Furfury1-2-methoxy-5-n-propyl-6,7-benzomorphan 2-Furfuryl-2-methoxy-5-isopropyl-6,7-benzomorphan 2-furfuryl-2'-acetoxy-5-methyl-6,7-benzomorphan 2-Furfuryl-2'-acetoxy-5-ethyl-6,7-benzomorphan Z-Furfuryl-2'-acetoxy-5-n-propy1-6,7-benzomorphan 2-Furfuryl-2-acetoxy-5-isopropyl-6,7-benzomorphan The compounds embraced by formula I are organic bases and therefore form acid addition salts with inorganic or organic acids. Examples of non-toxic, pharmacologically acceptable acid addition salts are those formed with hydrochloric acid, hydrobromic acid, bydroiodic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, propionic acid, butyric acid, valeric acid, pivalic acid, caproic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, citric acid, malic acid, benzoic acid, phthalic acid, cinnamic acid salicylic acid, ascorbic acid, 8-chlorotheophylline, methanesul fonic acid or the like.

The following examples illustrate the preparation of various compounds of the formula I and non-toxic, pharmacologically acceptable acid addition salts thereof.

EXAMPLE 1 2-Furfuryl-2'-hydroxy-a-5,9-dimethyl-6,7-

benzomorphan and its methanesulfonate by method A a. A mixture consisting of 21.7 gm (0.1 mol) of racemic 2 -hydroxy-a-5 ,9-dimethyl-6,7 -benzomorphan, 12.6 gm (0.15 mol) of sodium bicarbonate, 12.8 gm (0.1 1 mol) of furfuryl chloride, 60 ml of dimethylformamide and 100 ml of tetrahydrofuran was refluxed for three hours, accompanied by stirring. Thereafter, the reaction solution was evaporated in vacuo, the residue was shaken with a mixture of chloroform and water, and the chloroform phase was separated, washed twice with water, dried with sodium sulfate and evaporated. The residue was admixed with 100 ml of hot benzene, and the mixture was allowed to cool, whereby crystallization spontaneously ensued; the mixture was continuously stirred throughout the crystallization and until it had cooled to room temperature, and was then allowed to stand overnight in a refrigerator. Thereafter, the crystalline substance was collected by vacuum filtration and then washed first with benzene and subsequently with petroleum ether. The filter cake was allowed to dry in the air to yield a crystalline substance having a melting point of 104l06C. and comprising 1 mol of benzene of crystallization; subsequent drying of this crystalline product at 80C. until the weight remained constant yielded 50 gm (84% of theory) of the solvent-free, crystalline, racemic free base of the formula mpg 14 having a melting point of 121-122C.

b. The free base was suspended in 50 ml of absolute ethanol, and the suspension was just barely acidified by the addition of an ethanolic 2M solution of methanesulfonic acid, whereby a solution was formed. The resulting solution was admixed with absolute ether until it remained turbid, and then it was inoculated with crystals, whereupon crystallization ensued. The mixture was then stirred for about two hours, an equal amount of ether was added thereto, and it was stirred for two hours more. Subsequently, the mixture was allowed to stand overnight in a refrigerator, the crystalline substance was collected by vacuum filtration, and the filter cake was washed first with ethanol/ether and then with ether. The product was dried first in the air and then at C., yielding 35.5 gm (90.5% of theory) of the methanesulfonate of 2-furfuryl-2'-hydroxy-a-5,9-dimethyl- 6,7-benzomorphan, m.p. l62-164C. A sample recrystallized from ethanol/ether had a melting point of 163-165C.

EXAMPLE 2 Using a procedure analogous to that describedin Example 1(a), 74% of theory of (-)-2-furfuryl-2'-hydroxy- 01-5,9-dimethyl-6,7-benzomorphan, m.p. C., specific rotation [oz],, -129 (0 l gm/lOO ml methanol), was obtained from optically active (-)-2'- hydroxy-a-S,9-dimethyl-6,7-benzornorphan and furfuryl chloride. I

Analogously, when (+)-2'-hydroxy-a-5,9-dimethyl- 6,7-benzomorphan was used as the starting compound, the end product was (+)-2-furfuryl-2-hydroxy-a-5,9- dimethyl-6,7-benzomorphan, specific rotation [111 +l28 (c 1, methanol).

EXAMPLE 3" 2-[ Furylmethyl-( 3 -2 f-hydroxy-a-S-ethyl-9- methyl-6,7-benzomorphan and its hydrochloride by method A A mixture consisting of 2.31 gm (0.01 mol) of 2- hydroxy-a-S-ethyl-9-methyl-6,7-benzomorphan, 1.26 gm (0.015 mol) ofsodium bicarbonate, 1.28 gm (0.011 mol) of 3-chloromethyl-furan, 15 ml of dimethylformamide and 25 m1 of tetrahydrofuran was refluxed for four hours, accompanied by stirring. Thereafter, the reaction solution was evaporated in vacuo, and the residue was shaken with a mixture of chloroform and water. The chloroform phase was separated, washed twice with water, dried with sodium sulfate and evaporated. The residue, raw 2-[furylmethyl-(3' ')]-2'-hydroxy-a-5- ethyl-9-methyl-6,7-benzomorphan, was dissolved in 10-20 ml of absolute ethanol, the resulting solution was made just acid with ethanolic 5N hydrochloric acid, and the acidic solution was admixed with absolute ether until it remained turbid. The mixture was allowed to stand overnight in a refrigerator, the crystalline substance which had separated out during that time was collected by vacuum filtration, washed first with ethanol/ether and then with absolute ether, and dried in the air and then at 80C., yielding 3.0 gm (96.5% of theory) of the compound of the formula 11 ch N-CHQU HC].

having a melting point of 268C., which did not change after recrystallization from ethanol/ether.

EXAMPLE 4 Using a procedure analogous to that described in Example 1(a), 2-furfuryl-2'-hydroxy-a-5-methyl-9-ethyl- 6,7-benzomorphan was prepared from 2-hydroxy-a-5- methyl-9-ethyl-6,7-benzomorphan and furfuryl chloride.

lts methanesulfonate, m.p. l56l57C., was obtained with a yield of 55% of theory by the procedure described in Example l(b).

EXAMPLE 5 EXAMPLE 6 Using a procedure analogous to that described in Example l(a), 2-furfuryl-2-hydroxy-oz-5,9-diethyl-6,7- benzomorphan was prepared from 2'-hydroxy-a-5,9- diethyl-6,7-benzomorphan and furfuryl chloride.

Its hydrochloride, m. p. 236C., was obtained with a yield of 72% of theory by substituted hydrochloric acid for methansulfonic acid in the procedure described in Example l(b).

EXAMPLE 7 Using a procedure analogous to that described in Example 1 (a), 2-[furylmethyl-(3 ]-2-hydroxy-a-5 ,9- dimethyl-6,7-benzomorphan was prepared from 2'- hydroxy-a-S,9-dimethyl-6,7-benzomorphan and 3' chloromethyl-furan.

Its hydrochloride, m. p. 252C., was obtained with a yield of 78% of theory by substituting hydrochloric acid for methanesulfonic acid in the procedure described in Example l(b).

EXAMPLE 8 Using a procedure analogous to that described in Example l(a), 81% of theory of 2-[furylmethyl-(3")]-2- hydroxy-a-5-methyl-9-ethyl-6,7-benzomorphan, m. p. 268C., was obtained from 2-hydroxy-a-5-methyl-9- ethyl-6,7-benzomorphan and 3-chloromethyl-furan.

EXAMPLE 9 Using a procedure analogous to that described in Example l(a), 2-[furylmethyl-(3")]-2-hydroxy-a-5,9- diethyl-6,7-benzomorphan was prepared from 2'- hydroxy-a-S,9-diethyl-6,7benzomorphan and 3- chloromethyl-furan.

Its hydrochloride, m. p. 278C, was obtained with a yield of of theory by substituting hydrochloric acid for methanesulfonic acid in the procedure described in Example l(b).

EXAMPLE 10 Using a procedure analogous to that described in Example l(a), 2-[2' '-methyl-furylmethyl-( 3 )]-2 hydroxy-a-S,9-dimethyl-6,7-benzomorphan was prepared from 2'-hydroxy-a-5,9-dimethyl-6,7- benzomorphan and 2-1nethyl-3-chloromethylfuran.

Its hydrochloride, m. p. 270C, was obtained with a yield of 86% of theory by substituting hydrochloric acid for methanesulfonic acid in the procedure described in Example l(b).

EXAMPLE 1 1 Using a procedure analogous to that described in Example 1(a), 2-[2"-methyl-furylmethyl-(3 ")]2'- hydroxy-a-S-methyl-9-ethyl-6,7-benzomorphan was prepared from 2'-hydroxy oz-5-methyl-9-ethyl-6,7- benzomorphan and 2-methyl-3-chloromethyl-furan.

Its hydrochloride, m. p. 261C, was obtained with a yield of 89% of theory by substituting hydrochloric acid for methanesulfonic acid in the procedure described in Example l(b).

EXAMPLE 12 Using a procedure analogous to that described in Example 1(a), 2-[2"-rnethyl-furylmethyl-(3")]-2'- hydroxy-a-5-ethyl-9-methyl-6,7-benzomorphan was prepared from 2'-hydroxy-a-5-ethyl-9-methyl-6,7- benzomorphan and 2-methyl-3-chloromethyl-furan.

Its hydrochloride, m. p. 300C, was obtained with a yield of 97% of theory by substituting hydrochloric acid for methanesulfonic acid in the procedure described in Example l(b).

EXAMPLE l 3 Using a procedure analogous to that described in Example l(a), 71% of theory of 2-[2"-methylfurylmethyl-( 3 ]-2'-hydroxy-a-5 ,9-diethyl6,7- benzomorphan, mp. 216C, was obtained from 2- hydroxy-cz-S,9-diethyl-6,7-benzomo1phan and 2- methyl-3-chloromethyl-furan.

EXAMPLE 14 Using a procedure analogous to that described in Example l(a), 2-[2"-ethyl-furylmethyl-(3")]-2'- hydroxy-wS,9-dimethyl-6,7-benzomorphan was prepared from 2'-hydroxy-a-5 ,9-dimethyl-6,7- benzomorphan and 2-ethyl-3-chloromethyl-furan.

Its hydrochloride, in. p. l33l34C., was obtained with a yield of 94% of theory by substituting hydrochloric acid for methanesulfonic acid in the procedure described in Example l(b).

EXAMPLE 15 Using a procedure analogous to that described in Example l (a), 2-[ 2 -ethyl-furylmethyl-( 3 )]-2'- hydroxy-a-5-methyl-9-ethyl-6,7-benzomorphan was prepared from 2'-hydroxy-a-5-methyl-9-ethyl-6,7- benzomorphan and 2-ethyl-3-chloromethyl-furan.

lts hydrochloride, in. p. 285C, was obtained with a yield of 79% of theory by substituting hydrochloric acid for methanesulfonic acid in the procedure described in Example l(b).

EXAMPLE 16 Using a procedure analogous to that described in Example 1(a), 2-[ 3 "-ethyl-furylmethyl-( 3 ]-2- hydroxy-a-5-ethyl-9-methyl-6,7-benzomorphan was prepared from 2'-hydroxy-a-5-ethyl-9-methyl-6,7- benzomorphan and 2-ethyl-3-chloromethyl-furan.

Its hydrochloride, m. p. 165l70C., was obtained with a yield of 95% of theory by substituting hydrochloric acid for methanesulfonic acid in the procedure described in Example l(b).

EXAMPLE 17 Using a procedure analogous to that described in Example l (a), 2-[ 2' -ethyl-furylmethyl-( 3 )]-2 hydroxy-a-S,9-diethyl-6,7-benzomorphan was prepared from 2'-hydroxy-a-5,9-diethyl-6,7- benzomorphan and 2-ethyl-3-chloromethyl-furan.

Its hydrochloride, m. p. 265-266C., was obtained with a yield of 87% of theory by substituting hydrochloric acid for methanesulfonic acid in the procedure described in Example l(b).

EXAMPLE 18 Using a procedure analogous to that described in Example l(a), 2-furfuryl-2'-methoxy-a-5,9-dimethyl-6,7- benzomorphan was prepared from 2-methoxy-oz-5,9 dimethyl-6,7-benzomorphan and furfuryl chloride.

Its hydrochloride, m. p. 210C., was obtained by sub stituting hydrochloric acid for methanesulfonic acid in the procedure described in Example l(b).

EXAMPLE 19 Using a procedure analogous to that described in Example 1(a), 2-furfuryl-2-acetoxy-oz-5,9-dimethyl-6,7- benzomorphan was prepared from 2-acetoxy-a-5,9- dimethyl-6,7-benzomorphan and furfuryl chloride.

Its hydrochloride, m. p.. 134135C., was obtained by substituting hydrochloric acid for methanesulfonic acid in the procedure described in Example l(b).

EXAMPLE 2O 2-( 5 -Methyl-furfuryl)-2 -hydroxy-a-5 ,9-dimethyl- 6,7-benzomorphan and its hydrochloride by method B a. 2.17 gm (0.01 mol) of 2-hydroxy-a-5,9-dimethyl- 6,7-benzomorphan and 1.0 gm of an aqueous 30% formaldehyde solution (0.01 mol CH O) were successively dissolved in ml of aqueous 50% acetic acid. While stirring, the resulting solution was admixed with 0.82 gm (0.01 mol) of 2-methyl-furan, and the mixture was stirred for hours more. Thereafter, while adding ice, the solution was made alkaline with concentrated ammonia, the precipitate formed thereby was extracted with chloroform, and the organic extract solution was washed with water, dried with sodium sulfate and evaporated. For purification, the evaporation residue was dissolved in 50 ml of commercial chloroform, and the solution was chromatographed through a column charged with 75 gm of aluminum oxide (neutral, activity stage Ill). The first 200 to 250 ml of the eluate were collected and evaporated, yielding as a residue pure 2- (5-methyl-furfuryl)-2'-hydroxy-a-5,9-dimethyl-6,7- benzomorphan.

b. The residue was dissolved in 10 to 20 ml of ethanol, the resulting solution was acidified with ethanolic 5N hydrochloric acid, the acidic solution was admixed with absolute ether until it remained turbid, and the mixture was allowed to stand overnight in a refrigerator. Thereafter, the precipitate which had formed was collected by vacuum filtration and dried first in the air and then at C., yielding 2.1 gm (63% of theory) of the compound of the formula having a melting point of 232C. Upon recrystallization from ethanol/ether, the melting point of the hydrochloride did not change.

EXAMPLE 21 Using a procedure analogous to that described in Example 20, 2-(5-ethyl-furfuryl)-2"-hydroxy-a-5- methyl-9-ethyl-6,7-benzomorphan was prepared from 2-hydroxy-a-5-methyl-9-ethyl-6,7-benzomorphan, aqueous formaldehyde and Z-ethyI-furan.

Its hydrochloride, m. p. 192C., was obtained with a yield of 64% of theory.

EXAMPLE 22 Using a procedure analogous to that described in Example 20, 2-(5"-methyl-furfuryl)-2-hydroxy-a-5- methyl-9-ethyl-6,7-benzomorphan, m. p. 169C, was obtained from 2-hydroxy-a-5-methyl-9-ethyl-6,7- benzomorphan, aqueous formaldehyde and Z-methylfuran with a yield of 52% of theory.

EXAMPLE 23 EXAMPLE 24 Using a procedure analogous to that described in Example 20, 2-(5"-methyl-furfuryl)-2'-hydroxy-a-5,9- diethyl-6,7-benzomorphan, m. p. 147C., was obtained from 2'-hydroxy-a-5,9-diethyl-6,7-benzomorphan, aqueous formaldehyde and 2-methyl-furan with a yield of 47% of theory.

EXAMPLE 25 Using a procedure analogous to that described in Example 20, 2-(5"-ethyl-furfuryl)-2'-l1ydroxy-a-5,9- dimethyl-6,7-benzomorphan, m. p. 151C., was obtained from 2'-hydroxy-a-5,9-dimethyl-6,7- benzomorphan, aqueous formaldehyde and 2-ethylfuran with a yield of 71% of theory.

EXAMPLE 26 Using a procedure analogous to that described in Ex- 19 ample 20, 2-(5"-ethyl-furfuryl)-2'-hydroxy-a-5-ethyl- 9-methyl-6,7-benzomorphan, m. p. 172C, was obtained from 2'-hydroxy-oz-5-ethyl-9-methyl-6,7- benzomorphan, aqueous formaldehyde and 2-ethylfuran with a yield of 86% of theory.

EXAMPLE 27 Using a procedure analogous to that described in Example 20, 2-(5"-ethyl-furfuryl)-2'-hydroxy-a-5,9- diethyl-6,7-benzomorphan, m. p. 161C., was obtained from 2 -hydroxy-a- ,9-diethyl-6 ,7-benzomorphan, aqueous formaldehyde and 2-ethyl-furan with a yield of 48% of theory.

EXAMPLE 28 Using a procedure analogous to that described in Example 20, 2-[2"-methyl-furylmethyl-(3)]-2'- methoxy-a-5,9-dimethyl-6,7-benzomorphan was prepared from 2 -methoxy-a'5 ,9-dimethyl-6 ,7- benzomorphan, aqueous formaldehyde and 2-methylfuran.

lts hydrochloride, m. p. 128C., was obtained with a yield of 63% of theory.

EXAMPLE 29 Using a procedure analogous to that described in Example 20, 2-[2"-methyl-furylmethyl-(3")]-2-acetoxya-5,9-dimethyl-6,7-benzomorphan was prepared from 2'-acetoxy-cz-5,9-dimethyl-6,7-benzomorphan, aqueous formaldehyde and 2-methyl-furan.

lts hydrochloride, m. p. 212-2l5C., was obtained with a yield of 56% of theory.

EXAMPLE 30 2-( 3 -Methyl-furfuryl)-2 -hydroxy-a-5 ,9-diethyl- 6,7-benzomorphan by method D 2.45 gm (0.01 mol) of 2-hydroxy-a-5,9-diethyl-6,7 benzomorphan were dissolved in 35 ml of warm methanol, and, while stirring, the resulting solution was admixed with a solution of 2.5 gm of potassium carbonate in 4 ml of water. The mixed solution was allowed to cool to C., and then 1.74 gm (0.011 mol) of 3-methyl-furan-Z-carboxylic acid chloride were added over a period of ten minutes, and the resulting mixture was vigorously stirred for five hours. Thereafter, the methanol was removed by evaporation, the residue was shaken with a mixture of chloroform and water, the chloroform phase was separated, washed once with 2N hydrochloric acid and then twice with water, dried with sodium sulfate, and the chloroform was removed by evaporation. In order to remove residual traces of chloroform, the residue was redissolved in benzene, and the solution was again evaporated.

The residue, which consisted mainly of 2-[3"- methyl-furoyl-( 2 ]-2 -hydroxy-oz-5 ,9-diethyl-6,7- benzomorphan and contained a small amount of 2-(3"- methyl-2 '-furoyl )-2 3 '-methyl-2 -furoyloxy)-a-5 ,9- diethyl-6,7-benzomorphan (the pure major component had a melting point of 8789C. after crystallization from benzene), was dissolved in 50 ml of absolute tetrahydrofuran, and the resulting solution was added dropwise to a suspension of 0.76 gm (0.02 mol) of lithium aluminum hydride in ml of tetrahydrofuran at 5-l0C., accompanied by stirring. The resulting mixture was stirred overnight at room temperature, and then, while cooling it on an ice bath and vigorously stirring, 1.5 ml of water were added dropwise, and then 75 ml of a saturated aqueous diammonium tartrate solution were added. The resulting mixture was stirred for one hour and subsequently allowed to separate by standing in a separating funnel. The (upper) tetrahydrofuran phase was separated and evaporated, and the aqueous phase was extracted three times with 25 ml of chloroform each. The residue of the evaporated tetrahydrofuran phase was dissolved in the combined chloroform extracts, and the resulting solution was washed with water, dried with sodium sulfate and evaporated in vacuo. The residue was crystallized from methanol to yield 2.2 gm of the reaction product with a melting point of 195C. Recrystallization from aqueous methanol yielded 1.6 gm (47% of theory) of the pure compound of the formula having a melting point of 201C., which did not change upon further recrystallization.

EXAMPLE 3] 2-Furfuryl-2-hydroxy-a-5 ,9-dimethyl-6,7-

benzomorphan by method D N,O-Di-(2"-furoyl)-2-hydroxy-u-5,9-dimethyl- 6,7-benzomorphan A solution of 28.7 gm (0.22 mol) of furan-2- carboxylic acid chloride in 109 ml of absolute methylene chloride was added dropwise over a period of about one hour to a suspension of 21.7 gm (0.1 mol) of 2-hydroxy-a-5,9-dimethyl-6,7-benzomorphan in a mixture of 217 ml of absolute methylene chloride and 40 ml of triethylamine, accompanied by stirring, and the resulting mixture was refluxed for four hours. Thereafter, the reaction solution was allowed to cool and was then washed in the presence of ice, first twice with 100 ml of 2N hydrochloric acid each and subsequently three times with water. The methylene chloride phase was dried with sodium sulfate and then evaporated in vacuo, and the residue was caused to crystallize by digesting it with 250 ml of hot ethanol. The ethanolic mixture was stirred until it had cooled and was then allowed to stand overnight in a refrigerator. The crystalline substance was collected by vacuum filtration, washed with absolute ether and dried at C., yielding 38.5 gm of theory) of N,O-di-(2"- furoyl)-2-hydroxy-a-5,9-dimethyl-6,7-benzomorphan, m. p. l76l77C. A sample, recrystallized from ethanol, had a melting point of l77-l78C.

b. 2-Furfuryl-2'-hydroxy-a-5,9-dimethyl-6,7-

benzomorphan 38.5 gm (0.095 mol) of N,O-di-(2"-furoyl)-2- hydroxy-a-S,9-dimethyl-6,7-benzomorphan was dissolved in 770 ml of absolute tetrahydrofuran, and, while stirring and cooling, the solution was added dropwise to a suspension of 7.6 gm (0.2 mol) of lithium aluminum hydride in 200 ml of tetrahydrofuran. Thereafter, the mixture was stirred overnight at room temperature, and then, while cooling it on an ice bath and vigorously stirring it, 15 ml of water were added dropwise and subsequently 750 ml of a saturated aqueous diammonium tartrate solution. The resulting mixture was stirred for one hour more and was then worked up as described in Example 30. The residue from the evaporation of the chloroform solution was digested with 100 ml of hot benzene, and the mixture was stirred while crystallization occurred and until it had cooled. The cool mixture was allowed to stand in a refrigerator overnight, and then the crystalline substance was collected by vacuum filtration, washed first with benzene and then with petroleum ether, and dried first in the air and then in a drying chamber at 80C. until its weight remained constant. 27 gm (96% of theory) of the reaction product having a melting point of l21l22C. were obtained. It was identical to the end product of Example 1(a).

EXAMPLE 32 Using a procedure analogous to that described in Example 31, 71% of theory of 2-(3"-methyl-furfuryl)-2- hydroxy-a-S,9-dimethyl-6,7-benzomorphan, m. p. 1 19C., was obtained by reacting 2'-hydroxy-a-5,9- dimethyl-6,7-benzomorphan with 3-methyl-furan-2- carboxylic acid chloride, and reducing the N,O-di-[3"- methyl-furoyl-(2")]-a-5,9-dimethyl-6,7- benzomorphan formed therebywith lithium aluminum hydride.

EXAMPLE 33 Using a procedure analogous to that described in Example 31, 57% of theory of 2-(3"-methyl-furfuryl)-2'- hydroxy-a-5-methyl-9-ethyl-6,7-benzomorphan, m.p. 177C, was obtained by reacting 2-hydroxy-a-5- methyl-9-ethyl-6,7-benzomorphan with 3-methyl-furan-2-carboxylic acid chloride, and reducing the N ,O-di-[3 '-methyl-furoy1-(2 -a-5-methyl-9- ethyl-6,7-benzomorphan formed thereby with lithium aluminum hydride.

EXAMPLE 34 Using a procedure analogous to that described in Example 31, 92% of theory of 2-(3"-methyl-furfuryl)-2- hydroxy-a-S-ethyl-9-methyl-6,7-benzomorphan, m.p. 178C, was obtained by reacting 2-hydroxy-a-5-ethyl- 9-methy1-6,7-benzomorphan with 3-methyl-furan-2- carboxylic acid chloride, and reducing the N,O-di-[3 methyl-furoyl-(2")]-a-5-ethyl-9-methyl-6,7- benzomorphan formed thereby with lithium aluminum hydride.

EXAMPLE 35 Using a procedure analogous to that described in Example 30, 58% of theory of 2-(4"-methyl-furfuryl)-2'- hydroxy-a-S,9-dimethy1-6,7-benzomorphan, m.p. l44-146C, was obtained by reacting 2-hydroxy-a- 5,9-dimethyl-6,7-benzomorphan with 4-methylfuran- 2-carboxylic acid chloride, and reducing the N,O-di- [4 '-methyl-furoyl-( 2 ]-a-5 ,9-dimethyl-6,7- benzomorphan formed thereby with lithium aluminum hydride.

EXAMPLE 36 Using a procedure analogous to that described in Example 30, 67% of theory of 2-[4"-methyl-furylmethyl- (3 -2'-hydroxy-a-5 ,9-dimethyl-6,7-benzomorph an, m.p. 250C, was obtained by reacting 2'-hydroxy-a- 5,9-dimethyl-6,7-benzomorphan with 4-methy1-furan- 3-carboxylic acid chloride, and reducing the N,O-di- [4"-methyl-furoyl-(3")]-a-5,9-dimethy1-6,7- benzomorphan formed whereby with lithium aluminum hydride.

EXAMPLE 37 Using a procedure analogous to that described in Example 30, 83% of theory of 2-[5-methyl-furylmethy1- (3")]-2'-hydroxy-oz-5,9-dimethyl-6,7-benzomorphan, m.p. 248C, was obtained by reacting 2-hydroxy-oz 5,9-dimethyl-6,7-benzomorphan with S-methyl-furan- 3-carboxylic acid chloride, and reducing the N,O-di- [5"-methylfuroyl-(3")]-a-5,9-dimethyl-6,7- benzomorphan formed thereby with lithium aluminum hydride.

EXAMPLE 38 2-Furfuryl-2'-hydroxy-5-ethyl-6,7-benzomorphan and its hydrochloride by method A A mixture consisting of 2.17 gm (0.01 mol) of 2- hydroxy-5-ethyl-6,7-benzomorphan, 1.26 gm (0.015 mol) of sodium bicarbonate, 1.28 gm (0.011 mol) of furfuryl chloride, 6 ml of dimethylformamide and 10 ml of tetrahydrofuran was refluxed for three hours. Thereafter, the reaction solution was evaporated in vacuo, and the residue was shaken with a mixture of chloroform and water. The chloroform phase was separated, washed twice with water, dried with sodium sulfate and evaporated in vacuo. The residue, 2-furfuryl-2'- hydroxy-S-ethyl-6,7-benzomorphan, was dissolved in 10-20 ml of absolute methanol, the resulting solution was made just acid with ethanolic 5N hydrochloric acid, absolute ether was added to the acidic solution until it became turbid, and the mixture was allowed to stand overnight in a refrigerator. Thereafter, the crystalline precipitate which had formed was collected by vacuum filtration, washed once with ethanol/ether and once with absolute ether, and then dried first in the air and subsequently at C., yielding 2.7 gm (79.5% of theory) of the compound of the formula I I I H O N-CH I having a melting point of 242C. which did not change upon further recrystallization from ethanol/ether.

EXAMPLE 39 fluxed for four hours, accompanied by stirring. Thereafter, the reaction solution was evaporated in vacuo, the residue was shaken with a mixture of chloroform and water, and the chloroform phase was separated, washed twice with water, dried with sodium sulfate and evaporated in vacuo. The residue was crystallized from a mixture of 70 ml of acetone and ml of water, yielding 2.4 gm (73.5% of theory) of the compound of the formula N-cri y having a melting point of l59l 60C. Recrystallization from acetone/water raised the melting point to l60l61C.

EXAMPLE 40 Z-Furfuryl-Z'-hydroxy-5-isopropyl-6,7-

benzomorphan by method A a. N-Methyl-2'-hydroxy-5-isopropyl-6,7- benzomorphan was demethylated with phosgene in toluene, the unreacted N-methyl starting compound was separated, and the intermediate product was isolated and hydrolized with dilute hydrochloric acid to form the N-nor compound (yield: 48% of theory).

b. A mixture consisting of 2.3 gm (0.01 mol) of 2'- hydroxy-S-isopropyl-6,7-benzomorphan, 1.28 gm (0.01 1 mol) of furfuryl chloride, 1.26 gm (0.015 mol) of sodium bicarbonate, and 45 ml of a mixture of tetrahydrofuran and dimethylformamide (2:1) was refluxed for three hours. Thereafter, the reaction solution was evaporated in a rotary evaporator, the residue was taken up in chloroform, and the resulting solution was extracted several times with water, dried with sodium sulfate and evaporated in vacuo. The residue was chromatographed on an aluminum oxide (basic, activity stage 111) column with chloroform containing 1% methanol as the solvent. The eluate was evaporated in vacuo, and the residue was recrystallized from methanol, yielding 0.5 gm (16% of theory) of the compound of the formula EXAMPLE 41 Using a procedure analogous to that described in Example 38, 56.5% of theory of 2-furfuryl-2-hydroxy-5- methyl-6,7-benzomorphan, mp. 188C, was obtained from 2-hydroxy-5-methyl-6,7-benzomorphan and furfuryl chloride.

EXAMPLE 42 Using a procedure analogous to that described in Example 38, 74.5% of theory of 2-[furyl-methyl-(3")1-2'- hydroxy-5-methyl-6,7-benzomorphan, mp. 179C, was obtained from 2-hydroxy-5-methyl-6,7-benzomorphan and 3-chloromethylfuran.

EXAMPLE 43 Using a procedure analogous to that described in Example 38, of theory of 2-[furyl-methyl-(3")]-2'- hydroxy-S-ethyl-6,7-benzomorphan hydrochloride, mp. 225C, was obtained from 2'-hydroxy-5-ethyl-6,7- benzomorphan and S-chIoromethyl-furan.

EXAMPLE 44 Using a procedure analogous to that described in Example 38, 61% of theory of 2-[furyl-methyl-(3")]-2'- hydroxy-S-n-propyl-6,7-benzomorphan, mp. 182C, was prepared from 2-hydroXy-5-n-propyl-6,7- benzomorphan and 3-chloromethylfuran.

EXAMPLE 45 Using a procedure analogous to that described in Example 38, 81% of theory of 2-[2"-methyl-furylmethyl- (3)]-2-hydroxy-5-methyl-6,7-benzomorphan hydrochloride, m.p. 218C, was obtained from 2'-hydroxy-5- methyl-6,7-benzornorphan and 2-methyl-3- chloromethyl-furan.

EXAMPLE 46 Using a procedure analogous to that described in Example 38, 89% of theory of 2-[2"-methyl-fury1methyl- (3")]-2'-1ydroxy-5-ethyl-6,7-benzomorphan hydrochloride, mp. 25 3C, was obtained from 2'-hydroxy-5- ethyl-6,7-benzomorphan and 2-methyl-3- chloromethyl-furan.

EXAMPLE 47 EXAMPLE 48 Using a procedure analogous to that described in Example 38, (-)-2-furfuryl-2-hydroxy-5-methyl-6,7- benzomorphan, was prepared from (-)-2-hydroxy-5- methyl-6,7-benzomorphan and furfuryl chloride.

EXAMPLE 49 Using a procedure analogous to that described in Example 38, (+)-2-furfuryl-2'-hydroxy-5-methyl-6,7- benzomorphan, was prepared from (+)-2'-hydroxy-5- methyl-6,7-benzomorphan and furfuryl chloride.

EXAMPLE 50 Using a procedure analogous to that described in Ex- 25 ample 38, 2-furfuryl-2-acetoxy-5-ethyl-6,7- benzomorphan hydrochloride, m.p. 222-223C, was prepared from 2-acetoxy-5-ethyl-6,7-benzomorphan and furfuryl chloride.

EXAMPLE 51 Using a procedure analogous to that described in Example 38, 2-furfuryl-2-methoxy-5-ethyl-6,7- benzomorphan hydrochloride, m.p. 202C, was prepared from 2-methoxy-5-ethyl-6,7-benzomorphan and furfuryl chloride.

EXAMPLE 52 Using a procedure analogous to that described in Example 38, 2-[2"-methyl-furylmethyl-(3)]-2- methoxy-S-n-propyl-6,7-benzomorphan was prepared from 2'-methoxy-5-n-propyl-6,7-benzomorphan and 2-methyl-3-chloromethyl furan.

EXAMPLE 53 Using a procedure analogous to that described in EX- ample 38, 2-furfuryl-2'-methoxy-5-isopropyl-6,7- benzomorphan was prepared from 2'-methoxy-5- isopropyl-6,7-benzomorphan and furfuryl chloride.

EXAMPLE 54 Using a procedure analogous to that described in Example 38, 2-furfuryl-2-acetoxy-5-n-propyl-6,7- benzomorphan was prepared from 2-acetoxy-5-npropyl-6,7-benzomorphan and furfuryl chloride.

EXAMPLE 55 2(5"-Methyl-furfuryl)-2'-hydroxy-5-ethyl-6,7- benzomorphan and its hydrochloride by method A a. Using a procedure analogous to that described in Example 1(a), 2-(5"-formyl-furfuryl)-2'-hydroxy-5- ethyl-6,7-benzomorphan was prepared from 2'- hydroxy-S-ethyl-6,7-benzomorphan and 5-formylfurfuryl chloride.

b. A mixture consisting of 3.0 gm (0.01 mol) of 2- (5 '-formyl-furfuryl )-2 '-hydroxy-5-ethyl-6,7- benzomorphan, 5.0 gm of an 85% hydrazine hydrate solution, 2.3 gm of finely pulverized potassium hydroxide and 20 ml of triethyleneglycol was refluxed until the evolution of nitrogen had subsided (about 1.5 hours). Thereafter, the reaction mixture was diluted with 400 ml of water, ammonium chloride was added, and the mixture was extracted several times with chloroform. The combined chloroform extract solutions were washed with water, dried with sodium sulfate and evaporated, and the residue was purified by column chromatography on silicagel (200 gm; solvent system: Chloroform/methanol/concentrated ammonia 90: 1010.5). The fractions containing the pure reaction product were combined and evaporated, and the residue, 2 (5 '-methylfurfuryl )-2 -hydroxy-5-ethyl-6,7- benzomorphan, was converted in conventional manner into its hydrochloride, yielding 1.1 gm (32% of theory) of the compound of the formula HCl H 0 N-CHg- E 0] -CH3 having a melting point of 23023 1C.

EXAMPLE 56 2-( 5 -Methyl-furfuryl )-2 -hydroxy-5-methyl-6,7-

benzomorphan and its hydrochloride by method B a. A mixture consisting of 2.1 gm (0.01 mol) of 2'- hydroxy-5-methyl-6,7-benzomorphan, 1.1 gm of 30% formalin (0.011 mol formaldehyde), 0.9 gm (0.011 mol) of 2-methylfuran and 10 ml of aqueous 50% acetic acid was stirred at room temperature for 15 hours. Thereafter, the reaction solution was evaporated in vacuo, the residue was shaken with water, chlorform and ammonia (to alkaline reaction), the chloroform phase was separated, washed with water, dried with sodium sulfate and evaporated in vacuo, and the residue was crystallized from 20 ml of methanol, yielding 1.8 gm (60.5% of theory) of the free base of the formula swa -U -c1-1 EXAMPLE 57 2-( 5 '-Ethyl-furfuryl)-2'-hydroxy-5-ethyl-6,7- benzomorphan by method B A mixture consisting of 2.17 gm (0.01 mol) of 2'- hydroxy-S-ethyl-6,7-benzornorphan, 1.1 gm of 30% formalin (0.01 1 mol formaldehyde), 1.06 gm (0.011 mol) of Z-ethylfuran and 10 ml of aqueous 50% acetic acid was stirred at room temperature for 15 hours, and the reaction solution was worked up as described in the preceding example. The residue of the chloroform phase evaporation was crystallized from acetone/water, yielding 1.6 gm (49% of theory) of the free base of the formula having a melting point of 158C which rose to 161C upon further recrystallization from acetone/water.

EXAMPLE 58 EXAMPLE 59 Using a procedure analogous to that described in Example 56(a), 42% of theory of 2-(5"-ethyl-furfuryl)- 2'-hydroxy-5-methyl-6,7-benzomorphan, mp. 169C, was obtained from 2'-hydroxy-5-methyl-6,7- benzomorphan, aqueous formaldehyde and 2-ethylfuran.

EXAMPLE 60 Using a procedure analogous to that described in Example 56, 74% of theory of 2-(5-ethyl-furfuryl)-2'- hydroxy-S-n-propyl-6,7-benzomorphan hydrochloride, mp. 188C, was obtained from 2-hydroxy-5-n-propyl- 6,7-benzomorphan, aqueous formaldehyde and 2- ethyl-furan.

EXAMPLE 61 Using a procedure analogous to that described in Example 56(a), 2-(5"-methyl-furfuryl)-2-methoxy-5- methyl-6,7-benzomorphan was prepared from 2'- methoxy-S-methyl-6,7-benzomorphan, aqueous formaldehyde and 2-methyl-furan.

EXAMPLE 62 Using a procedure analogous to that described in Example 56(a), 2-(5"-methyl-furfuryl)-2'-acetoxy-5-npropyl-6,7-benzomorphan was prepared from 2'- acetoxy--n-propyl-6,7-benzomorphan, aqueous formaldehyde and Z-methyl-furan.

EXAMPLE 63 Using a procedure analogous to that described in Example 56(a), 2-(5"-ethyl-furfuryl)-2'-methoxy-5- methyl-6,7-benzomorphan was prepared from 2" methoxy-S-methyl-6,7-benzomorphan, aqueous formaldehyde and 2-ethyl-furan.

EXAMPLE 64 Using a procedure analogous to that described in Example 56(a), 2-(5"-ethyl-furfuryl)-2'-acetoxy-5-npropyl-6,7-benzomorphan was prepared from 2'- acetoxy-S-n-propyl-6,7-benzomorphan, aqueous formaldehyde and 2-ethyl-furan.

EXAMPLE 65 2-Furfuryl-2-hydroxy-5-ethyl-6,7-benzom0rphan and its hydrochloride by method C 2.17 gm (0.01 mol) of 2-hydroxy-5-ethyl-6,7- benzomorphan and 1.92 gm (0.02 mol) of freshly distilled furfurol were dissolved in 150 ml of methanol, and the resulting solution was immediately hydrogenated with hydrogen in the presence of 0.2 gm of palladized charcoal (10% Pd) at atmospheric. pressure, accompanied by shaking. After the calculated amount of hydrogen had been absorbed, the hydrogenation was terminated, the reaction solution was filtered, and the filtrate was evaporated. The brown residue was briefly refluxed with a mixture of chloroform/methanol/concentrated ammonia (:10:01), the insoluble matter was filtered off, and the filtrate was chromatographed on a silicagel (300 gm) column, using the above chloroform/methanol/ammonia mixture as the solvent system. The eluate fractions containing the reaction product were combined and evaporated in vacuo. The residue, 2-furfury1-2-hydroxy-5-methyl-6,7- benzomorphan, was converted into its hydrochloride as described in Example 1(b), yielding 0.8 gm (24% of theory) of the hydrochloride, mp. 242C.

EXAMPLE 66 Using a procedure analogous to that described in Example 65, 2-(3-ethyl-furfuryl)-2'-hydroxy-5-ethyl- 6,7-benzomorphan was prepared by catalytic hydrogenation of 2'-hydroxy-5-ethyl-6,7-benzomorphan in the presence of 3-ethylfurfurol.

EXAMPLE 67 Using a procedure analogous to that described in Example 65, 2-(4"-ethyl-furfuryl)-2'-hydroxy-5-npr0py1-6,7-benzomorphan was prepared by catalytic hydrogenation of 2'-hydroxy-5-n-propyl-6,7- benzomorphan in the presence of 4-ethyl-furfuro1.

EXAMPLE 68 Using a procedure analogous to that described in Example 65, 2-(5"-methyl-furfury1)-2-hydroxy-5-ethyl- 6,7-benzomorphan was prepared by catalytic hydrogenation of 2-hydroxy-5-ethyl-6,7-benzom0rphan in the presence of S-methylfurfurol.

EXAMPLE 69 Using a procedure analogous to that described in Example 65, 2-furfuryl-2'-hydroxy-5-n-propyl-6,7- benzomorphan, m.p. l73-174C, was prepared by catalytic hydrogenation of 2-hydroxy-5-n-propyl-6,7- benzomorphan in the presence of 5-chloro-furfurol, whereby the chloro-substituent on the furfuryl moiety was split off simultaneously with the reductive alkylation.

EXAMPLE 7O 2-(3"-Methyl-furfuryl)-2'-hydroxy-5-methy1-6,7- benzomorphan by method D a. 2.05 gm (0.01 mol) of 2'-hydroxy-5-methyl-6,7- benzomorphan were dissolved in 35 ml of warm methanol, and, while stirring, the warm solution was admixed with a solution of 2.5 gm of potassium carbonate in 4 ml of water. The mixed solution was allowed to cool to 20C, and then 1.74 gm (0.01 1 mol) of 3-methyl-furan- 2-carboxylic acid chloride were added over a period of 10 minutes, and the resulting mixture was vigorously stirred for five hours. Thereafter, the methanol was evaporated in vacuo, the residue was shaken with a mixture of chloroform and water, and the chloroform phase was separated, washed first with 2 N hydrochloric acid and then twice with water, dried with sodium sulfate and evaporated in vacuo. In order to remove residual traces of water and chloroform, the residue was dissolved in absolute methanol and the solution was again evaporated, leaving substantially pure 2-(3"- methyl-furoyl)-2'-hydroxy-5-methyl-6,7- benzomorphan.

b. The end product obtained in (a) was dissolved in 50 ml of absolute tetrahydrofuran and, while stirring and cooling, the solution was added dropwise to a suspension of 0.76 gm (0.02 mol) oflithium aluminum hydride in 25 ml of tetrahydrofuran at to C. The resulting mixture was stirred overnight at room temperature, and then, while cooling it on an ice bath and vigorously stirring it, 1.5 ml of water were added dropwise and subsequently 75 ml to a saturated aqueous diammonium tartrate solution were added, and the resulting mixture was stirred for one hour. Thereafter, the organic phase was allowed to separate from the aqueous phase in a separating funnel, and the tetrahydrofuran (upper) phase was isolated and evaporated in vacuo. The aqueous phase was washed three times with 25 ml of chloroform each, the chloroform extracts were combined, the residue from the evaporation of the tetrahydrofuran phase was dissolved therein, and the resulting chloroformic solution was washed with water, dried with sodium sulfate and evaporated in vacuo. The residue was crystallized first from petroleum ether and then from methanol/water, yielding 1.7 gm (57% of theory) of 2-( 3 '-methyl-furfuryl )-2 '-hydroxy-5- methyl-6,7-benzomorphan having a melting point of 162C which remained unchanged upon further recrystallization.

EXAMPLE 71 2-(3"-Methyl'furfuryl)-2'-hydroxy-5-n-propyl-6,7- benzomorphan by method D a. 2.3 gm (0.01 mol) of 2-hydroxy-5-n-propyl-6,7- benzomorphan were suspended in 23 ml of absolute methylene chloride, 4 ml of triethylamine were added to the suspension, and then, while stirring the mixture, 3.2 gm (0.022 mol) of 3-methyl-furan-Z-carboxylic acid chloride were added dropwise thereto, and the resulting mixture was refluxed for four hours. Thereafter, the reaction solution was washed, in the presence of ice, first twice with 10 ml of 2 N hydrochloric acid each and then three times with water, and the methylene chloride phase was dried with sodium sulfate and then evaporated. In order to remove residual traces of methylene chloride and water, the residue was redissolved in absolute benzene, and the solution was again evaporated in vacuo, leaving substantially pure N,O-di-(3"- methyl-2"-furoyl)-2-hydroxy-5-n-propyl-6,7- benzomorphan.

b. The end product obtained in (a) was reduced with 0.76 gm (0.02 mol) of lithium aluminum hydride in a manner analogous to that described in Example 70(b), which yielded 2.2 gm (67.5% of theory) of 2-(3"- methyl-furfuryl)-2-hydroxy-5-n-propyl-6,7- benzomorphan, mp. 120C.

EXAMPLE 72 Using a procedure analogous to that described in Example 70, 2-(3"-methy1-furfuryl)-2'-hydroxy-5-ethyl- 6,7-benzomorphan hydrochloride, mp. 171C, was prepared from 2-hydroxy-5-ethyl-6,7-benzomorphan and 3-methyl-furan-2-carboxylic acid chloride. The yield was 21.5% of theory.

EXAMPLE 73 Using a procedure analogous to that described in Example 70, 2-(4-methyl-furfuryl)-2'-hydroxy-5-ethyl- 6,7-benzomorphan hydrochloride, mp. 214C, was prepared from 2'-hydroxy-5-ethyl-6,7-benzomorphan and 4-methyl-furan-2-carboxylic acid chloride. The yield was 57.5% of theory.

EXAMPLE 74 Using a procedure analogous to that described in Example 70, 2-[4 -methyl-furylmethyl-( 3 )]-2 hydroxy-5-methyl-6,7-benzomorphan hydrochloride, mp. 27 8C, was prepared from 2'-hydroxy-5-ethyl-6,7- benzomorphan and 4-methyl-furan-3-carboxylic acid chloride. The yield was 60% of theory.

EXAMPLE 75 Using a procedure analogous to' that described in Example 70, 2-[5 "-methy1-fury1methy1-(3")]-2'- hydroxy-S-ethyl-6,7-benzomorphan hydrochloride, mp. 218C, was prepared from 2'-hydroxy-5-ethyl-6,7- benzomorphan and 5-methylfuran-3-carboxylic acid chloride. The yield was 58% of theory.

EXAMPLE 76 Using a procedure analogous to that described in Example 70, 2-(3"-methyl-furfuryl)-2'-methoxy-5- methyl-6,7-benzomorphan was prepared from 2'- methoxy-5-methyl-6,7-benzomorphan and 3-methyl-furan-2-carboxylic acid chloride.

EXAMPLE 77 Using a procedure analogous to that described in Example 70, 2-(5"-methyl-furfuryl)-2-methoxy-5-npropyl-6,7-benzomorphan was prepared from 2'- methoxy-5-n-propyl-6,7-benzomorphan and 3-methyl-furan-2-carboxylic acid.

EXAMPLE 78 Using a procedure analogous to that described in Example 70, 2-[fury1methyl-( 3 ]-2'-methoxy-5-ethylbenzomorphan was prepared from 2'-methoxy-5-ethyl- 6,7-benzomorphan and furan-3-carboxylic acid chloride.

EXAMPLE 79 EXAMPLE 80 2-[ 2 '-Methyl-furylmethyl-( 3 ]-2'-methoxy-5- ethyl-6,7-benzomorphan was prepared by methylating 2-[ 2 '-methyl-furylmethyl-( 3 )]-2'-hydroxy-5-ethyl- 6,7-benzomrphan (the end product of Example 46) with diazomethane in tetrahydrofuran/ether.

EXAMPLE 81 2-[ 2 '-Methyl-furylmethyl-( 3 ]-2-acetoxy-5-ethyl- 5 6,7-benzomorphan was prepared by acetylating 2-[2"- methyl-furylmethyl-( 3 -2'-hydroxy-5-ethyl-6,7- benzomorphan with acetyl chloride in pyridine.

EXAMPLE 82 Using a procedure analogous to that described in Example l (a), 2-furfuryl-2-hydroxy-5-n-butyl-6,7- benzomorphan, m.p. l58l60C, of the formula was prepared from 2'-hydroxy-5-n-butyl-6,7- benzomorphan and furfuryl chloride. The yield was 56% of theory.

EXAMPLE 83 Using a procedure analogous to that described in Example 70, 45% of theory of 2-furfuryl-2'-hydroxy-6,7-

benzomorphan of the formula was obtained from 1.42 gm of 2-hydroxy-6,7- benzomorphan and furan-Z-carboxylic acid chloride. Its hydrochloride had a melting point of l9l-l92C after recrystallization from ethanol/ether.

EXAMPLE 84 EXAMPLE 85 Using a procedure analogous to that described in Example 71, of theory of 2-[2-methyl-furylmethyl- (3")]-2-hydroxy-6,7-benzomorphan was obtained from 2-hydroxy-6,7-benzomorphan and 2-methyl-furan-3-carboxylic acid chloride. Its hydro- 32 chloride had a melting point of 222-223C after recrystallization from ethanol/ether.

EXAMPLE 86 Using a procedure analogous to that described in Example 70, 52% of theory of 2'-(3"-methyl-furfuryl)-2- hydroxy-6,7-benzomorphan was obtained from 2-hydroxy-6,7-benzornorphan and 3-methyl-furan-2- carboxylic acid chloride. lts hydrochloride had a melting point of 235236C.

The compounds embraced by formula I above and their non-toxic, pharmacologically acceptable acid addition salts, have useful pharmacodynamic properties. More particularly, they exhibit opiate antagonistic, non-narcotic analgesic and antitussive activities in warm-blooded animals, such as mice and rats.

The compounds of the formula I were tested for analgesic activity in mice and rats by various standard pharmacological test methods, namely:

1. The I-Iaffner method [Deutsche Medizinische Wochenschrift 55, 731 (1929)]; 2. The hot-plate method [1. Pharmacol. exp.

Therap. 80, 300 (1944)]; and 3. The writhing test [J. Pharmacol. exp. Therap. 154,

319 (1966)]. In the l-laffner test, they were found to be inactive. However, in the hot-plate test and the writhing test they exhibited distinct dose-dependent analgesic activities. In accordance with prevailing teachings [Adv. Chem. Ser. 49, 162-169 (1964)], analgesic inactivity in the Hatfner test is normally an indication that the compounds possess no rnorphine-like physical dependence capacity, i.e., do not produce narcotic addiction. On the other hand, however, analgesic activity in the hotplate test and the writhing test proves that they are effective analgesics.

For pharmaceutical purposes the compounds of the formula I or their non-toxic acid addition salts are administered to warm'blooded animals perorally, enterally or parenterally as active ingredients in customary dosage unit compositions, that is, compositions in dosage unit form consisting essentially of an inert pharmaceutical carrier and one effective dosage unit of the active ingredient, such as tablets, coated pills, capsules, wafers, powders, solutions, suspensions, emulsions, syrups, suppositories and the like. One effective analgesic and antitussive dosage unit of the compounds of the formula I or their non-toxic salts is from 0.166 to 5.0 mgm/kg body weight, preferably 0.83 to 2.5 mgm/kg body weight.

The following examples illustrate a few pharmaceutical dosage unit compositions comprising a compound of the formula I or a non-toxic acid addition salt thereof as an active ingredient and represent the best modes contemplated of putting the invention into practical use. The parts are parts by weight unless otherwise specified.

EXAMPLE 87 Tablets 2-Furfuryl-2'-hydroxy-x-5 ,9-dimethyl- 6,7-benzomorphan Lactose 50.0 parts 95.0 pans -Continued Corn starch 45.0 parts Colloidal silicic acid 2.0 parts Soluble starch 5.0 parts Magnesium stearate 3.0 parts Total 200.0 parts Preparation:

The benzomorphan compound is intimately admixed with the lactose and the corn starch, the mixture is moistened with an aqueous solution of the soluble starch, the moist mass is forced through a l mm-mesh screen, the resulting granulate is dried at 40C, the dry granulate is admixed with the colloidal silicic acid, and the composition is compressed into 200 mgm-tablets in a conventional tablet making machine. Each tablet contains 50 mgm of the benzomorphan compound and is an oral dosage unit composition with effective analgesic and antitussive actions.

EXAMPLE 88 Coated pills The pill core composition is compounded from the following ingredients:

6,7-benzomorphan hydrochloride 75.0 parts Lactose 100.0 parts Corn starch 65.0 parts Colloidal silicic acid 2.0 parts Soluble starch 5.0 parts Magnesium stearate 3.0 parts Total 250.0 parts Preparation:

The ingredients are compounded in the same manner as in Example 87, and the composition is compressed into 250 mgm-pill cores which are subsequently coated with a thin shell consisting essentially of a mixture of sugar,talcum and gum arabic and finally polished with beeswax. Each coated pill contains 75 mgm of the henzomorphan compound and is an oral dosage unit composition with effective analgesic and antitussive activities.

EXAMPLE 89 Suppositories The suppository composition is compounded from the following ingredients:

hydroxy-a-S,9-dimethyl-6,7-benzomorphan 50.0 parts Lactose 250.0 parts Suppository base (e.g. cocoa butter) 1400.0 parts Total 1700.0 parts Preparation:

The benzomorphan compound is intimately admixed with the lactose, and the mixture is blended with the aid of an immersion homogenizer into the suppository base which had previously been melted and cooled to about 40C. 1700 mgm-portions of the composition are poured into cooled suppository molds and allowed to harden therein. Each suppository contains 50 mgm of the benzomorphan compound and is a rectal dosage unit composition with effective analgesic and antitussive actions.

EXAMPLE Hypodermic solution The solution is compounded from the following ingredients:

2-Furfuryl-2' -hydroxy-a-S,9-dimethyl- 6,7-benzomorphan methanesulfonate 75.0 parts Sodium chloride 5.0 parts Double-distilled water q.s.ad 2000.0 parts by vol.

EXAMPLE 91 Drop solution The solution is compounded from the following ingredients:

2-Furfuryl-2 '-hydroxy-0z-5 ,9-dimethyl- 6.7-benzomorphan 0.70 parts Methyl p-hydroxy-benzoate 0.07 parts Propyl p-hydroxy-benzoate 003 parts Demineralized water q.s.ad 100.0 parts by vol.

Preparation:

The benzomorphan compound and the p-hydroxybenzoates are dissolved in the demineralized water, the solution is filtered, and the filtrate is filled into mlbottles. 10 ml of the solution contain 70 mgm of the benzomorphan compound and are an oral dosage unit composition with effective analgesic and antitussive actions.

Analogous results are obtained when any one of the other benzomorphans embraced by formula I or a nontoxic acid addition salt thereof is substituted for the particular benzomorphan in Examples 87 through 91. Likewise, the amount of active ingredient in these illustrative examples may be varied to achieve the dosage unit range set forth above, and the amounts and nature of the inert pharmaceutical carrier ingredients may be varied to meet particular requirements.

While the present invention has been illustrated with the aid of certain specific embodiments thereof, it will be readily apparent to others skilled in the art that the invention is not limited to these particular embodiments, and that various changes and modifications may be made withour departing from the spirit of the invention or the scope of the appended claims.

We claim:

1. A pharmaceutical dosage unit composition having analgesic and antitussive activity consisting essentially of an inert pharmaceutical carrier and an effective analgesic or antitussive amount of a racemic mixture of a compound of the formula wherein R is hydrogen, methyl or acetyl,

R is hydrogen, methyl, ethyl, n-propyl, isopropyl or butyl, and

R and R are each hydrogen, methyl or ethyl; or an optically active isomer component thereof; or a non-toxic, pharmacologically acceptable acid addition salt of said racemic mixture or optically active isomer.

2. A composition of claim 1, wherein R is hydrogen,

R, is hydrogen, methyl, ethyl, n-propyl, isopropyl or n-butyl, and

R and R are each hydrogen, methyl or ethyl.

3. A composition of claim 1, wherein said compound is 2-furfuryl-2 '-hydroxy-a-5 ,9-dimethyl-6,7- benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.

4. A composition of claim 1, wherein said compound is 2-[3"-methyl-furylmethyl-(2")]-2'-hydroxy-a-5,9- dimethyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.

5. A composition of claim 1, wherein said compound is 2-[2"-methyl-furylmethyl-(3")]-2-hydroxy-a-5,9- dimethyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.

6. A composition of claim 1, wherein said compound is 2-furfuryl-2-hydroxy-5-ethyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.

7. A composition of claim 1, wherein said compound is 2-furfuryl-2'-hydroxy-5-methyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.

8. A composition of claim 1, wherein said compound is 2-( 3 '-methyl-furfuryl)-2 '-hydroxy-5-ethyl-6,7- benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.

9. A composition of claim 1, wherein said compound is 2-( 3 -methyl-furfuryl )-2 '-hydroxy-5 -methyl-6,7- benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.

10. A composition of claim 1, wherein said compound is 2-[2' '-methyl-furylmethyl-( 3 -2 -hydroxy- 5-ethyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.

11. A composition of claim 1, wherein said compound is 2-[2' -methyl-furylmethyl-( 3 ]-2 '-hydroxy- 5-methyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.

12. The method of alleviating pain or suppressing the cough reflex in a warm-blooded animal in need of such treatment, which comprises perorally, parentarally or rectally administering to said animal an effective analgesic or antitussive amount of a racemic mixture of a compound of the formula R1 t ia R3 wherein R is hydrogen, methyl or acetyl, R, is hydrogen, methyl, ethyl, n-propyl, isopropyl or butyl, and R and R are each hydrogen, methyl or ethyl; or an optically active isomer component thereof; or a nontoxic, pharmacologically acceptable acid addition salt of said racemic mixture or optically active isomer.

13. The method of claim 12, wherein R is hydrogen, R is hydrogen, methyl, ethyl, n-propyl, isopropyl or n-butyl, and R and R are each hydrogen, methyl or ethyl.

Patent No,

Inventofls) TED STATES PATENT OFFICE Dated June 3, 1975 HERBERT MERZ, ADOLF LANGBEIN, HELMUT WICK and KLAUS STOCKHAUS It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below;

ESE/AL] line 9 line 55 "5,91" should read 5,9-

After insert "2" should read 2' 2"" should read 2' "2"" should read 2' (3"-] should read (3") H "2[3"-" should read 2-[2 "-(3"methyl2"-furoyloxy) should read -(3'-methyl-2'-furoyloxy) Signed and Scaled this twenty-sixth Day of August 1975 Arrest:

RUTH c. MASON C.MARSHALL DANN Arresting Officer Commissioner oj'latenls and Trademarks 

1. A PHARMACEUTICAL DOSAGE UNIT COMPOSITION HAVING ANALGESIC AND ANTITUSSIVE ACTIVITY CONSISTING ESSENTIALLY OF AN INERT PHARMACEUTICAL CARRIER AND AN EFFECTIVE ANALGESIC OR ANTITUSSIVE AMOUNT OF A RACEMIC MIXTURE OF A COMPOUND OF THE FORMULA
 1. A pharmaceutical dosage unit composition having analgesic and antitussive activity consisting essentially of an inert pharmaceutical carrier and an effective analgesic or antitussive amount of a racemic mixture of a compound of the formula
 2. A composition of claim 1, wherein R is hydrogen, R1 is hydrogen, methyl, ethyl, n-propyl, isopropyl or n-butyl, and R2 and R3 are each hydrogen, methyl or ethyl.
 3. A composition of claim 1, wherein said compound is 2-furfuryl-2''-hydroxy- Alpha -5,9-dimethyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.
 4. A composition of claim 1, wherein said compound is 2-(3''''-methyl-furylmethyl-(2''''))-2''-hydroxy- Alpha -5,9-dimethyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.
 5. A composition of claim 1, wherein said compound is 2-(2''''-methyl-furylmethyl-(3''''))-2''-hydroxy- Alpha -5,9-dimethyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.
 6. A composition of claim 1, wherein said compound is 2-furfuryl-2''-hydroxy-5-ethyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.
 7. A composition of claim 1, wherein said compound is 2-furfuryl-2''-hydroxy-5-methyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addItion salt thereof.
 8. A composition of claim 1, wherein said compound is 2-(3''''-methyl-furfuryl)-2''-hydroxy-5-ethyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.
 9. A composition of claim 1, wherein said compound is 2-(3''''-methyl-furfuryl)-2''-hydroxy-5-methyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.
 10. A composition of claim 1, wherein said compound is 2-(2''''-methyl-furylmethyl-(3''''))-2''-hydroxy-5-ethyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.
 11. A composition of claim 1, wherein said compound is 2-(2''''-methyl-furylmethyl-(3''''))-2''-hydroxy-5-methyl-6,7-benzomorphan or a non-toxic, pharmacologically acceptable acid addition salt thereof.
 12. The method of alleviating pain or suppressing the cough reflex in a warm-blooded animal in need of such treatment, which comprises perorally, parentarally or rectally administering to said animal an effective analgesic or antitussive amount of a racemic mixture of a compound of the formula 